STOCK TITAN
  1. Home
  2. SEC Filings
  3. ALMR
  4. [Form 4] Alamar Biosciences, Inc. Insider Trading Activity

Alamar Biosciences: Qiming sells 187,636 shares

The sales were attributed through four record-holding entities, and were not marked as made under a Rule 10b5-1 plan.

Available on EDGAR Accepted by SEC EDGAR
Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Alamar Biosciences, Inc. (ALMR) reported indirect sales of 187,636 common shares on October 30 and November 2, 2026, at reported per-share prices from $29.84 to $33.31. The seven reporting entities, each identified as a ten percent owner, were Qiming Corporate GP VI, Ltd.; Qiming Managing Directors Fund VI, L.P.; Qiming Venture Partners VI, L.P.; Qiming GP VIII, LLC; Qiming Venture Partners VIII Investments, LLC; Qiming GP VIII-HC, LLC; and Qiming Venture Partners VIII-HC, L.P. The shares were held of record by the four investment entities named in that list. The report does not mark the sales as made under a Rule 10b5-1 plan. Footnotes state that related general partners may be deemed to have voting and dispositive power and disclaim beneficial ownership except to the extent of their proportionate pecuniary interests.

Insider Qiming Corporate GP VI, Ltd., Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming GP VIII, LLC, Qiming Venture Partners VIII Investments, LLC, Qiming GP VIII-HC, LLC, Qiming Venture Partners VIII-HC, L.P.
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold 187,636 shs ($5.68M)
Type Security Shares Price Value
Sale Common Stock F9, F2 763 $29.84 $23K
Sale Common Stock F2 3 $30.63 $91.89
Sale Common Stock F9, F6 28,404 $29.84 $848K
Sale Common Stock F6 131 $30.63 $4K
Sale Common Stock F9, F7 6,628 $29.84 $198K
Sale Common Stock F7 30 $30.63 $918.90
Sale Common Stock F9, F8 7,935 $29.84 $237K
Sale Common Stock F8 36 $30.63 $1K
Sale Common Stock F1, F2 1,309 $29.93 $39K
Sale Common Stock F3, F2 1,080 $30.70 $33K
Sale Common Stock F4, F2 92 $31.96 $3K
Sale Common Stock F5, F2 31 $33.31 $1K
Sale Common Stock F1, F6 48,659 $29.93 $1.46M
Sale Common Stock F3, F6 40,112 $30.70 $1.23M
Sale Common Stock F4, F6 3,400 $31.96 $109K
Sale Common Stock F5, F6 1,169 $33.31 $39K
Sale Common Stock F1, F7 11,354 $29.93 $340K
Sale Common Stock F3, F7 9,359 $30.70 $287K
Sale Common Stock F4, F7 793 $31.96 $25K
Sale Common Stock F5, F7 273 $33.31 $9K
Sale Common Stock F1, F8 13,593 $29.93 $407K
Sale Common Stock F3, F8 11,205 $30.70 $344K
Sale Common Stock F4, F8 950 $31.96 $30K
Sale Common Stock F5, F8 327 $33.31 $11K
Holdings After Transaction: Common Stock — 1,670,550 shares (Indirect, See footnote)
Footnotes (9)
  1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.49, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1), (3), (4), (5) and (9) to this Form 4.
  2. F2. These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.46, inclusive.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.52 to $32.465, inclusive.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.68 to $33.59, inclusive.
  6. F6. These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  7. F7. These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  8. F8. These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
  9. F9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.44, inclusive.
Shares sold 187,636 common shares Sales reported October 30 and November 2, 2026
Reported sale transactions 24 transactions Reported on October 30 and November 2, 2026
Reported per-share price $29.84 per share Reported for sales on October 30 and November 2, 2026; footnotes identify weighted-average pricing for the cited transactions
Reported per-share price $29.93 per share Reported for sales on October 30, 2026; the cited footnote identifies weighted-average pricing
Reported per-share price $30.63 per share Reported for sales on November 2, 2026
Reported per-share price $30.70 per share Reported for sales on October 30, 2026; the cited footnote identifies weighted-average pricing
Reported per-share price $31.96 per share Reported for sales on October 30, 2026; the cited footnote identifies weighted-average pricing
Reported per-share price $33.31 per share Reported for sales on October 30, 2026; the cited footnote identifies weighted-average pricing
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
voting and dispositive power regulatory
"may be deemed to have voting and dispositive power"
beneficial ownership regulatory
"disclaims beneficial ownership of such shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest regulatory
"except to the extent of its proportionate pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ALMR shares did Qiming entities sell, and when?
Qiming entities reported 187,636 shares sold on October 30 and November 2, 2026. The sales were not marked as made under a Rule 10b5-1 plan; the shares were held of record by four entities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Qiming Corporate GP VI, Ltd.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)		2. Issuer Name and Ticker or Trading Symbol
Alamar Biosciences, Inc. [ ALMR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock10/30/2026S1,309D$29.93(1)162,882ISee footnote(2)
Common Stock10/30/2026S1,080D$30.7(3)161,802ISee footnote(2)
Common Stock10/30/2026S92D$31.96(4)161,710ISee footnote(2)
Common Stock10/30/2026S31D$33.31(5)161,679ISee footnote(2)
Common Stock10/30/2026S48,659D$29.93(1)6,053,320ISee footnote(6)
Common Stock10/30/2026S40,112D$30.7(3)6,013,208ISee footnote(6)
Common Stock10/30/2026S3,400D$31.96(4)6,009,808ISee footnote(6)
Common Stock10/30/2026S1,169D$33.31(5)6,008,639ISee footnote(6)
Common Stock10/30/2026S11,354D$29.93(1)1,412,427ISee footnote(7)
Common Stock10/30/2026S9,359D$30.7(3)1,403,068ISee footnote(7)
Common Stock10/30/2026S793D$31.96(4)1,402,275ISee footnote(7)
Common Stock10/30/2026S273D$33.31(5)1,402,002ISee footnote(7)
Common Stock10/30/2026S13,593D$29.93(1)1,691,003ISee footnote(8)
Common Stock10/30/2026S11,205D$30.7(3)1,679,798ISee footnote(8)
Common Stock10/30/2026S950D$31.96(4)1,678,848ISee footnote(8)
Common Stock10/30/2026S327D$33.31(5)1,678,521ISee footnote(8)
Common Stock11/02/2026S763D$29.84(9)160,916ISee footnote(2)
Common Stock11/02/2026S3D$30.63160,913ISee footnote(2)
Common Stock11/02/2026S28,404D$29.84(9)5,980,235ISee footnote(6)
Common Stock11/02/2026S131D$30.635,980,104ISee footnote(6)
Common Stock11/02/2026S6,628D$29.84(9)1,395,374ISee footnote(7)
Common Stock11/02/2026S30D$30.631,395,344ISee footnote(7)
Common Stock11/02/2026S7,935D$29.84(9)1,670,586ISee footnote(8)
Common Stock11/02/2026S36D$30.631,670,550ISee footnote(8)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Qiming Corporate GP VI, Ltd.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Managing Directors Fund VI, L.P.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Venture Partners VI, L.P.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming GP VIII, LLC
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Venture Partners VIII Investments, LLC
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming GP VIII-HC, LLC
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Qiming Venture Partners VIII-HC, L.P.
(Last)(First)(Middle)
C/O MAPLES CORPORATE SERVICES LIMITED
PO BOX 309
(Street)
UGLAND HOUSEGRAND CAYMANKY1-1104
(City)(State)(Zip)
CAYMAN ISLANDS
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.49, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1), (3), (4), (5) and (9) to this Form 4.
2. These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.46, inclusive.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.52 to $32.465, inclusive.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.68 to $33.59, inclusive.
6. These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
7. These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
8. These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.44, inclusive.
Qiming GP VIII, LLC By: /s/ Ho Man LAM/Authorized Signatory11/03/2026
Qiming Venture Partners VIII Investments, LLC By: /s/ Ho Man LAM/Manager11/03/2026
Qiming GP VIII-HC, LLC By: /s/ Ho Man LAM/Authorized Signatory11/03/2026
Qiming Venture Partners VIII-HC, L.P. By: /s/ Ho Man LAM/Authorized Signatory11/03/2026
Qiming Corporate GP VI, Ltd By: /s/ Ho Man LAM/Authorized Signatory11/03/2026
Qiming Managing Directors Fund VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory11/03/2026
Qiming Venture Partners VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory11/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on ALMR

All ALMR news

Trending in the feed

AMD
AMD Reports Third Quarter 2026 Financial Results Open the live feed